Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Counter-regulatory responses are critical to prevent hypoglycemia in subjects with type 2 diabetes. This is particularly important in insulin-treated patients. This study explored the effect of the glucagon-like peptide 1 receptor agonist lixisenatide on the hormonal counter-regulatory responses to insulin-induced hypoglycemia when added to basal insulin therapy in subjects with type 2 diabetes.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Endokrinologi och diabetes
Originalspråkengelska
Sidor (från-till)242-249
TidskriftDiabetes Care
Volym39
Utgivningsnummer2
StatusPublished - 2016
PublikationskategoriForskning
Peer review utfördJa

Nedladdningar

Ingen tillgänglig data

Relaterad forskningsoutput

Johan Farngren, 2019, Lund: Lund University, Faculty of Medicine. 65 s.

Forskningsoutput: AvhandlingDoktorsavhandling (monografi)

Visa alla (1)